Amgen (AMGN) Convertible Debt (2009 - 2010)
Amgen (AMGN) posted Convertible Debt of $2.2 billion for Q1 2010, down 51.22% on a QoQ basis from $4.5 billion in Q4 2009.
Analysis
Amgen (AMGN) Convertible Debt (2009 - 2010) Analysis & Trends
Amgen has reported Convertible Debt for 2 years, with the latest figure at $2.2 billion in Q1 2010.
- On a quarterly basis, Convertible Debt changed N/A year-over-year to $2.2 billion in Q1 2010; TTM through Mar 2010 was $2.2 billion, a N/A change from a year earlier, with the FY2009 full-year figure at $4.5 billion, changed N/A from the prior year.
- Convertible Debt was $2.2 billion for Q1 2010 at Amgen, down from $4.5 billion in the prior quarter.
- The five-year high for Convertible Debt was $4.5 billion in Q4 2009, with the low at $2.2 billion in Q1 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2010 | 2.20 Bn |
| Dec 31, 2009 | 4.51 Bn |
| Sep 30, 2009 | 4.45 Bn |
| Jun 30, 2009 | 4.38 Bn |